Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Imaging changes in synaptic acetylcholine availability in living human subjects.

Esterlis I, Hannestad JO, Bois F, Sewell RA, Tyndale RF, Seibyl JP, Picciotto MR, Laruelle M, Carson RE, Cosgrove KP.

J Nucl Med. 2013 Jan;54(1):78-82. doi: 10.2967/jnumed.112.111922. Epub 2012 Nov 15.

2.

Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5-I-A-85380.

Fujita M, Al-Tikriti MS, Tamagnan G, Zoghbi SS, Bozkurt A, Baldwin RM, Innis RB.

Synapse. 2003 Jun 1;48(3):116-22.

PMID:
12645036
3.

123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility.

Staley JK, van Dyck CH, Weinzimmer D, Brenner E, Baldwin RM, Tamagnan GD, Riccardi P, Mitsis E, Seibyl JP.

J Nucl Med. 2005 Sep;46(9):1466-72.

4.

Single photon emission computed tomography experience with (S)-5-[(123)I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers.

Brasić JR, Zhou Y, Musachio JL, Hilton J, Fan H, Crabb A, Endres CJ, Reinhardt MJ, Dogan AS, Alexander M, Rousset O, Maris MA, Galecki J, Nandi A, Wong DF.

Synapse. 2009 Apr;63(4):339-58. doi: 10.1002/syn.20611.

5.

Quantification of smoking-induced occupancy of beta2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding.

Esterlis I, Cosgrove KP, Batis JC, Bois F, Stiklus SM, Perkins E, Seibyl JP, Carson RE, Staley JK.

J Nucl Med. 2010 Aug;51(8):1226-33. doi: 10.2967/jnumed.109.072447. Epub 2010 Jul 21.

6.

123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual phase.

Cosgrove KP, Mitsis EM, Bois F, Frohlich E, Tamagnan GD, Krantzler E, Perry E, Maciejewski PK, Epperson CN, Allen S, O'malley S, Mazure CM, Seibyl JP, van Dyck CH, Staley JK.

J Nucl Med. 2007 Oct;48(10):1633-40. Epub 2007 Sep 14.

7.

Measurement of plasma metabolites of (S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates.

Zoghbi SS, Tamagnan G, Baldwin MF, Al-Tikriti MS, Amici L, Seibyl JP, Innis RB.

Nucl Med Biol. 2001 Jan;28(1):91-6.

PMID:
11182569
8.

Sex differences in availability of β2*-nicotinic acetylcholine receptors in recently abstinent tobacco smokers.

Cosgrove KP, Esterlis I, McKee SA, Bois F, Seibyl JP, Mazure CM, Krishnan-Sarin S, Staley JK, Picciotto MR, O'Malley SS.

Arch Gen Psychiatry. 2012 Apr;69(4):418-27. doi: 10.1001/archgenpsychiatry.2011.1465.

9.

Evaluation of the sensitivity of the novel α4β2* nicotinic acetylcholine receptor PET radioligand 18F-(-)-NCFHEB to increases in synaptic acetylcholine levels in rhesus monkeys.

Gallezot JD, Esterlis I, Bois F, Zheng MQ, Lin SF, Kloczynski T, Krystal JH, Huang Y, Sabri O, Carson RE, Cosgrove KP.

Synapse. 2014 Nov;68(11):556-64. doi: 10.1002/syn.21767. Epub 2014 Jul 28.

10.

[123I]5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptor availability in the aging human brain.

Mitsis EM, Cosgrove KP, Staley JK, Frohlich EB, Bois F, Tamagnan GD, Estok KM, Seibyl JP, Van Dyck CH.

Ann N Y Acad Sci. 2007 Feb;1097:168-70.

PMID:
17413019
11.

Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors.

Doll F, Dolci L, Valette H, Hinnen F, Vaufrey F, Guenther I, Fuseau C, Coulon C, Bottlaender M, Crouzel C.

J Med Chem. 1999 Jun 17;42(12):2251-9.

PMID:
10377231
12.

123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment.

Mitsis EM, Reech KM, Bois F, Tamagnan GD, Macavoy MG, Seibyl JP, Staley JK, van Dyck CH.

J Nucl Med. 2009 Sep;50(9):1455-63. doi: 10.2967/jnumed.109.064030. Epub 2009 Aug 18.

13.

beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking.

Cosgrove KP, Batis J, Bois F, Maciejewski PK, Esterlis I, Kloczynski T, Stiklus S, Krishnan-Sarin S, O'Malley S, Perry E, Tamagnan G, Seibyl JP, Staley JK.

Arch Gen Psychiatry. 2009 Jun;66(6):666-76. doi: 10.1001/archgenpsychiatry.2009.41.

14.

5-[I-125/123]lodo-3(2(S)-azetidinylmethoxy)pyridine, a radioiodinated analog of A-85380 for in vivo studies of central nicotinic acetylcholine receptors.

Musachio JL, Scheffel U, Finley PA, Zhan Y, Mochizuki T, Wagner HN Jr, Dannals RF.

Life Sci. 1998;62(22):PL 351-7.

PMID:
9627107
15.

Acute effects of physostigmine and galantamine on the binding of [18F]fluoro-A-85380: a PET study in monkeys.

Valette H, Bottlaender M, Dollé F, Coulon C, Ottaviani M, Syrota A.

Synapse. 2005 Jun 15;56(4):217-21.

PMID:
15803498
16.

PET imaging of acetylcholinesterase inhibitor-induced effects on α4β2 nicotinic acetylcholine receptor binding.

Hillmer AT, Wooten DW, Farhoud M, Higgins AT, Lao PJ, Barnhart TE, Mukherjee J, Christian BT.

Synapse. 2013 Dec;67(12):882-6. doi: 10.1002/syn.21698. Epub 2013 Aug 30.

17.

Age-related decline in nicotinic receptor availability with [(123)I]5-IA-85380 SPECT.

Mitsis EM, Cosgrove KP, Staley JK, Bois F, Frohlich EB, Tamagnan GD, Estok KM, Seibyl JP, van Dyck CH.

Neurobiol Aging. 2009 Sep;30(9):1490-7. doi: 10.1016/j.neurobiolaging.2007.12.008. Epub 2008 Feb 1.

18.

Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon.

Musachio JL, Villemagne VL, Scheffel UA, Dannals RF, Dogan AS, Yokoi F, Wong DF.

Nucl Med Biol. 1999 Feb;26(2):201-7.

PMID:
10100220
19.

Effect of acetylcholinesterase inhibitors on the binding of nicotinic alpha4beta2 receptor PET radiotracer, (18)F-nifene: A measure of acetylcholine competition.

Easwaramoorthy B, Pichika R, Collins D, Potkin SG, Leslie FM, Mukherjee J.

Synapse. 2007 Jan;61(1):29-36.

PMID:
17068780
20.

Effects of extracellular acetylcholine on muscarinic receptor binding assessed by [125I]dexetimide and a simple probe.

Sánchez-Roa PM, Wagner HN Jr, Villemagne VL, London ED, Lever JR.

Eur J Pharmacol. 1998 Oct 9;358(3):207-11.

PMID:
9822886

Supplemental Content

Support Center